Alnylam Pharmaceuticals, Inc (ALNY) shares are up almost 8% pre-market after the company reported positive results from a trial of its ALN-HBV for the treatment of hepatitis B virus in chimpanzees.
“Alnylam’s new ALN-HBV program is a mature, pre-clinical asset acquired through the company’s acquisition of Sirna from Merck. We are very encouraged by the data we are presenting for the first time today, which we believe constitute the most robust proof-of-concept pre-clinical data to date with an RNAi therapeutic for the treatment of HBV,” said company vice president Laura Sepp-Lorenzino.
The stock recently traded at $58.50 and has moved in a 52-week range of $25.57 – $112.57.
Latest posts by Anne-Marie Jackson (see all)
- Humpback Whales May Face A Fair Number Of Boat Collisions - Apr 25, 2017
- Elon Musk Confirmed His Dreams And Position In Neuralink - Apr 23, 2017
- Toyota Is Launching A Rental Service For Its Robotic Leg Brace - Apr 17, 2017